Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vital Signs

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5,402 result(s) found for: Vital Signs. Displaying page 1 of 271.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-005903-34 Sponsor Protocol Number: KKSMUW2011-09 Start Date*: 2012-05-04
    Sponsor Name:G. L. Pharma GmbH
    Full Title: Phase II, single centre, double blinded, cross-over dose confirmation study using two morphine-naloxone i.v. solutions
    Medical condition: Treatment of opioid dependence
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014824-40 Sponsor Protocol Number: ART621-290 Start Date*: 2009-11-03
    Sponsor Name:Arana Therapeutics Ltd
    Full Title: An open label follow on study to evaluate the long-term safety, tolerability and efficacy of ART621 following fortnightly administration for 48 weeks in patients with rheumatoid arthritis concomita...
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000790-38 Sponsor Protocol Number: CRSV 604A 2203 Start Date*: 2008-07-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of oral RSV604 in healthy adults experimentally infected with respiratory syncytial virus
    Medical condition: infection with respiratory syncytial virus
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-002500-91 Sponsor Protocol Number: RPC01-3001 Start Date*: 2015-10-12
    Sponsor Name:Celgene International II Sàrl (CIS II)
    Full Title: A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) GB (Completed) ES (Completed) BG (Completed) SK (Completed) GR (Completed) PL (Completed) LV (Completed) EE (Completed) LT (Completed) PT (Completed) SE (Completed) HR (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2004-000686-35 Sponsor Protocol Number: CLIC477D2302E01 Start Date*: 2005-04-29
    Sponsor Name:Novartis Pharma AG
    Full Title: A 52-week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2000 mg/d in the treatment of manic episodes of bipolar I disorder
    Medical condition: Bipolar I disorder, manic and mixed episodes
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003004-31 Sponsor Protocol Number: NP25139 Start Date*: 2016-08-09
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir (Tamiflu) in the Treatment of Children 1 to 12 Years of Age With Influenza Infection
    Medical condition: Influenza
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-002851-92 Sponsor Protocol Number: AN-EPI3334 Start Date*: 2016-09-08
    Sponsor Name:ANTHERA Pharmaceuticals, Inc.
    Full Title: An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis
    Medical condition: Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Ongoing) CZ (Completed) PL (Prematurely Ended) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004532-10 Sponsor Protocol Number: POI-1 Start Date*: 2018-05-23
    Sponsor Name:Karolinska University Hospital
    Full Title: Effects of immunomodulatory therapy on gonadal function in women with autoimmune premature ovarian insufficiency
    Medical condition: Autoimmune premature ovarian insufficiency
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10052660 Hypergonadotropic hypogonadism LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing) NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000687-27 Sponsor Protocol Number: CLIC477D2303E01 Start Date*: 2004-11-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A 52 week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2500 mg/d in the treatment of manic episodes of bipolar I disorder
    Medical condition: Bipolar I disorder, manic and mixed episodes DSM-IV criteria 296.0, 296.4 or 296.6
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Prematurely Ended) SK (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-000794-47 Sponsor Protocol Number: CTIN816A12201 Start Date*: 2023-01-13
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A randomized, multi-centric, placebo-controlled, participant and investigator-blinded study to evaluate the safety, tolerability and efficacy of TIN816 in adult patients at risk for acute kidney in...
    Medical condition: Acute kidney injury
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10069339 Acute kidney injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Ongoing) CZ (Ongoing) HU (Ongoing) EE (Ongoing) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001259-36 Sponsor Protocol Number: D2452L00010 Start Date*: 2006-06-16
    Sponsor Name:AstraZeneca AB
    Full Title: A randomised, parallel group, single blind, multicentre, 9-month, phase IV study in a primary care setting, comparing treatment guided by clinical symptoms and signs and NT-proBNP vs treatment guid...
    Medical condition: Heart Failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003256-29 Sponsor Protocol Number: MNX2008 Start Date*: 2009-06-17
    Sponsor Name:Charité – Universitätsmedizin Berlin
    Full Title: Effect of Methylnaltrexone on Postoperative Analgesic Demands
    Medical condition: Pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002023-11 Sponsor Protocol Number: 53718678RSV3001 Start Date*: 2021-02-16
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rilematovir in Infants and Children (≥28 Days to ≤5 Years of Age) and Subsequently in Neonates (...
    Medical condition: Respiratory Syncytial Virus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BG (Completed) DE (Prematurely Ended) SE (Completed) CZ (Completed) HU (Completed) BE (Completed) PL (Completed) Outside EU/EEA EE (Completed) LV (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-007853-30 Sponsor Protocol Number: sNN0031-001 Start Date*: 2009-01-28
    Sponsor Name:NeuroNova AB
    Full Title: A randomized, double-blind, placebo controlled, safety and tolerability study of intracerebroventricular administration of sNN0031 to patients with idiopathic Parkinson's disease (PD) of moderate s...
    Medical condition: Idiopathic Parkinson's disease (PD) of moderate severity (modified Hoehn & Yahr Stage IIb - III)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001792-37 Sponsor Protocol Number: CQGE031C2302E1 Start Date*: 2020-04-22
    Sponsor Name:Novartis Pharma AG
    Full Title: A multi-center, double-blinded and open-label extension study to evaluate the efficacy and safety of ligelizumab as retreatment, self-administered therapy and monotherapy in Chronic Spontaneous Urt...
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) FR (Prematurely Ended) CZ (Completed) ES (Prematurely Ended) DE (Prematurely Ended) AT (Completed) GR (Prematurely Ended) EE (Completed) IT (Prematurely Ended) BE (Completed) SK (Prematurely Ended) DK (Prematurely Ended) PL (Prematurely Ended) NL (Temporarily Halted) BG (Prematurely Ended) HR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2004-002157-30 Sponsor Protocol Number: 01-03-TL-715-005 Start Date*: 2004-12-01
    Sponsor Name:Takeda Europe R&D Centre Ltd. (TEuR&D)
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Oral TAK-715 in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2020-000067-23 Sponsor Protocol Number: PN-1007-001 Start Date*: 2020-09-21
    Sponsor Name:Polyneuron Pharmaceuticals AG
    Full Title: First in Human Study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of PPSGG in anti-MAG neuropathy patients
    Medical condition: anti-MAG neuropathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10066137 Anti-MAG neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002613-30 Sponsor Protocol Number: GH-3899 Start Date*: 2016-04-25
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 12-month, open-labelled, randomised, parallel-group, multi-centre, interventional trial to evaluate the efficacy and safety of recombinant human growth hormone (hGH) (Norditropin® Nordilet®) ther...
    Medical condition: Idiopathic short stature
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004859 10066333 Idiopathic short stature LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000299-40 Sponsor Protocol Number: CRAD001C2121 Start Date*: 2016-05-12
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open label, two-way crossover study investigating the relative bioavailability of a single 5 mg dose of everolimus administered as either 5x1 mg everolimus intact tablets or 5x1 mg ev...
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-015931-33 Sponsor Protocol Number: 42801PAI3010 Start Date*: 2010-05-07
    Sponsor Name:JANSSEN-CILAG
    Full Title: An open label, prospective, multicenter, single-arm clinical trial to investigate the safety and the analgesic effectiveness of a low dose (4 mg) OROS hydromorphone hydrochloride as starting dose...
    Medical condition: patients with chronic moderate to severe malignant pain which has not been adequately controlled by previous treatment with NSAIDs, COX-2 inhibitors or paracetamol.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10058019 Cancer pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 07:07:03 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA